ONCY · Oncolytics Biotech Inc
$0.86
+0.01 (+0.78%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we expect that our existing cash resources, even when considered together with capital that may be raised under our equity distribution arrangements, are sufficient to fund near‑term operating milestones but are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our condensed consolidated financial statements included in this quarterly report. These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$108.38M
Shares
127.51M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Diluted EPS
-$0.30
0%
FY2025
Operating Cash Flow
-$20.11M
-1.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $28.73M | $25.54M | |
| $386K | $975K | |
| $45K | $2.84M | |
| -$28.9M | -$23.32M | |
| USD/shares | -$0.30 | -$0.30 |
| USD/shares | -$0.30 | -$0.30 |
| shares | 95.86M | 76.48M |
| shares | 95.86M | 76.48M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | -$28,725,000 | -$25,542,000 |
Key facts
CIK
1129928
CUSIP
68237V103
13F (30d)
57 filings
57 filers
Visit website
Investor relations